Overcoming Clinical Trial Delays with Enhanced Patient Recruitment:

In the complex journey of drug development, one of the biggest hurdles is patient recruitment. This challenge significantly contributes to delays in the FDA approval process. Dr. Harsha Rajasimha points out that 85% of clinical trials are delayed due to recruitment issues. The drug approval process, often referred to as the "valley of death," is both time-consuming and costly, with only a small percentage of drugs ultimately getting approved. To address these delays, Dr. Harsha Rajasimha points to innovative solutions such as AI-based platforms for patient identification, simplified trial protocols, and digital tools for trial management. 

Tools such as Meld aim to streamline patient enrollment and improve the efficiency of clinical trials, and provide sponsors with real-time insights into site activity. 

For more information on these trends you can check out the following article